Full Year Results 

Oxford Biomedica gives bear scenario

Oxford Biomedica gives bear scenario

Oxford Biomedica (OXB) has not yet experienced “any significant impact” from the coronavirus crisis. But in a “rigorous assessment” of downside risks, the group noted it needed external funding to sustain its operations. The gene and cell editing specialist added that revenues could, hypothetically, slip by almost 30 per cent were it to attract fewer new customers and lower demand from its existing client-base. In that scenario, the group said it “would not be able to generate sufficient cash flows to support its level of activities beyond the third quarter”.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now